Transgenomic, Inc. (TBIO) Announces Medicare Coverage for Clopidogrel (Plavix®) Response Test
7/24/2012 9:49:52 AM
OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (OTCBB: TBIO) today announced that National Government Services, the designated Medicare fiscal intermediary in Connecticut, has confirmed coverage for its proprietary Clopidogrel Genetic Absorption Activation Panel (C-GAAP, formerly PGxPREDICT®:Clopidogrel). As a result of this coverage, the 48 million Americans currently covered by Medicare will have access to this genetic test. The C-GAAP is a clinically validated diagnostic test that identifies patients with genetic variations in CYP2C19, a gene whose effect is described in clopidogrel’s label, and ABCB1, a gene that is unique to Transgenomic’s panel and is covered by issued and pending patents owned by Transgenomic.